MoonLake Immunotherapeutics Reports Strong Q1 2025 Financial Results and Business Update
ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biopharmaceutical company based in Switzerland, has announced its first quarter 2025 financial results and provided a comprehensive business update. The company, which focuses on developing innovative therapies for inflammatory diseases, continues to make significant strides in the development of its lead investigational Nanobody®, sonelokimab.
Progress in Clinical Development
MoonLake Immunotherapeutics has continued to advance the development of sonelokimab across a diverse portfolio of indications. Notably, the company has completed patient enrollment in the Phase 3 VELA program for hidradenitis suppurativa (HS). This milestone replicates the successful Phase 2 MIRA trial, reinforcing the potential of sonelokimab in treating HS. Additionally, the company is progressing with Phase 3 studies in psoriatic arthritis (PsA) and adolescent HS, alongside Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA).
An interim readout from the Phase 2 LEDA study in PPP has been presented, showcasing sonelokimab’s potential in an indication where no approved therapeutics currently exist in the US and Europe. This development further derisks the overall program for sonelokimab.
Financial Position and Funding
As of the end of the first quarter, MoonLake Immunotherapeutics reported having $480.1 million in cash, cash equivalents, and short-term marketable debt securities. The company has successfully closed a debt facility, securing up to $500 million in non-dilutive funds. This financial maneuver extends the company’s expected cash runway into 2028, providing a solid foundation for continued research and development activities.
Company Overview
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, with its primary operations focused on unlocking the potential of sonelokimab. The company aims to improve patient outcomes by addressing inflammation through innovative therapies. MoonLake Immunotherapeutics is traded on the Nasdaq stock exchange and maintains a market capitalization of approximately $2.39 billion as of May 8, 2025. For more information, visit their website at www.moonlaketx.com .
This article provides a concise overview of MoonLake Immunotherapeutics’ recent financial results and business developments, highlighting key milestones in the clinical development of sonelokimab and the company’s robust financial position.